Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease
Open Access
- 11 February 2021
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 36 (6) , 1451-1455
Abstract
Background: Homozygous and compound heterozygous variants in glucocerebrosidase (GBA) can cause Gaucher disease (GD), whereas heterozygous variants increase the risk of developing Parkinson's disease (PD). GD patients display altered peripheral immune proteins. However, it is unknown if these are altered in GBA carriers with PD.Objectives: To determine whether plasma cytokines and immune biomarkers associated with GD are also altered in GBA carriers with or without PD.Methods: Inflammatory cytokines and established GD biomarkers, ferritin, CD162, CCL18, and chitotriosidase (28 biomarkers) were measured in GBA pathogenic variant carriers with (n = 135) and without (n = 83) PD, and non‐carriers with (n = 75) and without PD (n = 77).Results: PD patients with biallelic pathogenic variants in GBA had elevated plasma levels of ferritin, CCL18, and MIP1α. These biomarkers were not elevated in heterozygous GBA carriers.Conclusion: GD plasma biomarkers are not promising candidates for stratifying the risk for PD in carriers of heterozygous GBA pathogenic variants. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder SocietyKeywords
Funding Information
- Michael J. Fox Foundation for Parkinson's Research (MJFF‐14764)
- National Institute of Neurological Disorders and Stroke (K02NS080915)
This publication has 33 references indexed in Scilit:
- Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counselingGenetics in Medicine, 2012
- Gaucher disease geneGBAfunctions in immune regulationProceedings of the National Academy of Sciences, 2012
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's DiseaseNew England Journal of Medicine, 2009
- Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onsetNeurology, 2008
- Epidemiology and natural history of Gaucher's diseaseEuropean Journal of Internal Medicine, 2006
- Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic interventionBlood, 2004
- Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?Molecular Genetics and Metabolism, 2003
- Occurrence of Parkinson's syndrome in type 1 Gaucher diseaseQJM: An International Journal of Medicine, 1996
- Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.Journal of Clinical Investigation, 1994
- Serum ferritin concentration in Gaucher's disease.BMJ, 1983